Ionis Closer To First Wholly-Owned Drug Launch With Olezarsen Phase III Success
Drug Targets apoC-III To Lower Triglycerides
Executive Summary
Ionis will seek US and EU approvals to treat familial chylomicronemia syndrome in the first half of 2024. Phase III data in the larger severe hypertriglyceridemia indication are due in late 2024 or early 2025.
You may also be interested in...
AstraZeneca/Ionis’s Eplontersen Shows Competitive Efficacy In ATTR Polyneuropathy At 66 Weeks
Patients continued to improve across all three Phase III NEURO-TTRansform co-primary endpoints with 29 more weeks of treatment, setting up eplontersen to challenge Alnylam’s Amvuttra.
Ionis Buys Out Akcea As Cardiovascular Pipeline Blooms
The RNA-drug developer, which is buying the approximately 24% of Akcea it doesn't already own for around $500m, highlighted the maturing pipeline in a cardiovascular overview.
Seismic Rumbles Into Clinic With $121m For Novel Immunology Biologics
Less than two years after its $101m series A round, Seismic’s machine-learning powered IMPACT platform for biologics drug discovery yielded two clinical trial-ready assets worthy of a $121m series B.